相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG
Katie E. Hadley et al.
BMC CANCER (2014)
Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
B. Solomon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer
Mark A. Socinski et al.
CLINICAL CANCER RESEARCH (2013)
P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Ziyad Binkhathlan et al.
CURRENT CANCER DRUG TARGETS (2013)
Non-Small Cell Lung Cancer, Version 2.2013 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation
Hyeong Ryul Kim et al.
MOLECULAR ONCOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
(R)-[11C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP
Kerstin Roemermann et al.
NUCLEAR MEDICINE AND BIOLOGY (2013)
Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non-Small Cell Lung Cancer
Jim Sang et al.
CANCER DISCOVERY (2013)
Modulation of MDR1 and MRP3 Gene Expression in Lung Cancer Cells after Paclitaxel and Carboplatin Exposure
Consolacion Melguizo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Takaaki Sasaki et al.
CANCER RESEARCH (2011)
Role for NAD(P)H:quinone Oxidoreductase 1 and Manganese-Dependent Superoxide Dismutase in 17-(Allylamino)-17-demethoxygeldanamycin-Induced Heat Shock Protein 90 Inhibition in Pancreatic Cancer Cells
David Siegel et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models
E. Normant et al.
ONCOGENE (2011)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
Zhao Chen et al.
CANCER RESEARCH (2010)
Detection of gastric carcinoma-associated MG7-Ag by serum immuno-PCR assay in a high-risk Chinese population, with implication for screening
Lian Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells
Nathatie Gaspar et al.
CANCER RESEARCH (2009)
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90
Charles Erlichman
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis
Marissa V. Powers et al.
CANCER CELL (2008)
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel
Ayana Sawai et al.
CANCER RESEARCH (2008)
Targeting Hsp90: small-molecule inhibitors and their clinical development
Tony Taldone et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Heat shock protein 90 inhibition in lung cancer
Takeshi Shimamura et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
Swee Y. Sharp et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism
Andrea K. McCollum et al.
CANCER RESEARCH (2006)
Cyclosporin A is a broad-spectrum multidrug. resistance modulator
M Qadir et al.
CLINICAL CANCER RESEARCH (2005)
Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats
MJ Egorin et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Increased drug delivery to the brain by P-glycoprotein inhibition
AJM Sadeque et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
分享论文
